Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;79(4):659-663.e2.
doi: 10.1016/j.jaad.2018.02.007. Epub 2018 Feb 10.

The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey

Benjamin H Kaffenberger  1 , Alice Hinton  2 , Somashekar G Krishna  3
Affiliations

The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey

Benjamin H Kaffenberger et al. J Am Acad Dermatol. 2018 Oct.

Abstract

Background: Whether the underlying disease affects the outcomes in pyoderma gangrenosum (PG) is unclear.

Objectives: To determine the impact of comorbid disease associations and concomitant procedural treatments on patient outcomes in hospitalizations of patients with PG.

Methods: A cross-sectional analysis of the National Inpatient Sample for hospitalizations of patients with PG from the years 2002 to 2011, analyzing in-hospital mortality rate and health care resource utilization.

Results: Inflammatory bowel disease was the most frequent comorbid association, followed by inflammatory arthritis, hematologic malignancies/dyscrasia, and vasculitis. Multivariable modeling showed that vasculitis and hematologic malignancy/dyscrasia, when compared with inflammatory bowel disease, were associated with a 4-fold to 6-fold increased risk of in-hospital mortality and increasing health care resource utilization. Inpatient procedural interventions, including skin grafts, biopsies, and debridement, did not affect mortality and were associated with an increased length of stay.

Limitations: The database does not account for outpatient follow-up; additionally, there was a low rate of coded comorbid conditions.

Conclusions: Comprehensive evaluation to determine the underlying comorbidity for patients with PG is important for patient risk stratification.

Keywords: Crohn's disease; biopsy; debridement; hospital; inflammatory bowel disease; mortality; neutrophilic disease; pyoderma gangrenosum; rheumatoid arthritis; ulcerative colitis; utilization; vasculitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: BHK is an investigator for Biogen, Celgene, Eli Lilly Co, and XBiotech. The other investigators do not have conflicts of interest to disclose.

Comment in

References

    1. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: A retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011 Jan;165:1244–1250. doi: 10.1111/j.1365-2133.2011.10565.x. 2000. - DOI - PubMed
    1. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: A review and update on new therapies. J Am Acad Dermatol. 2010;62(4):646–654. doi: 10.1016/j.jaad.2009.05.030. - DOI - PubMed
    1. Bennett M, Jackson J, Jorizzo J, Fleischer A, JR, White W, Callen J. Pyoderma Gangrenosum: A comparison of Typical and Atypical Forms with an Emphasis on Time to Remission. Case Review of 86 Patients from Institutions. Medicine (Baltimore) 2000;79:37–46. - PubMed
    1. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34(3):395–409-2. - PubMed
    1. Wollina U. Pyoderma gangrenosum — a systemic disease ? Clin Dermatol. 2015;33(5):527–530. doi: 10.1016/j.clindermatol.2015.05.003. - DOI - PubMed

MeSH terms